id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-328657-rlrs7spv	Park, Jay J H	Clinical trials of disease stages in COVID 19: complicated and often misinterpreted	2020-08-20		.txt	text/plain	878	49	33	The initial remdesivir randomised trial on patients receiving treatment in hospital, in which the median time to remdesivir initiation after symptom onset was 11 days, did not show important statistical benefits for time to clinical improvement. 6 A subsequent randomised trial that initiated remdesivir at a median of 9 days after symptom onset, by contrast, found a shorter recovery time in patients with less severe pulmonary disease than in the placebo group. Conversely, the dexamethasone findings in the RECOVERY trial found benefit in patients with more severe disease requiring oxygen or respiratory support, 5 supporting an antiinflammatory effect when inflammation pathology predominates. 9 Although it is clear that some therapies have no clinical benefits in patients admitted to hospital, there is much uncertainty, and thus clinical equipoise, to justify continuing clinical trials in other COVID-19 disease states. Most ongoing trials are focusing on participants admitted to hospital, and generalising their findings to ambulatory patients might potentially harm opportunities to identify effective outpatient treatments.	./cache/cord-328657-rlrs7spv.txt	./txt/cord-328657-rlrs7spv.txt